


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition comprising, ~~as active principles,~~
- (i) at least one α -glucosidase inhibitor that is miglitol, voglibose or emiglitate and
- (ii) at least one acid that is compound of the formula (I), in combination with one or more pharmaceutically acceptable excipients, the compound of the formula (I) being defined as follows:



~~in which the groups A and B are chosen, independently of each other, from:~~

- ~~– a mono-, bi- or tricyclic aryl group containing from 6 to 14 carbon atoms;~~
- ~~– a heteroaromatic group chosen from pyridyl, pyrimidyl, pyrrolyl, furyl and thienyl groups;~~
- ~~– an alkyl group containing from 1 to 14 carbon atoms;~~
- ~~– a cycloalkyl group containing from 5 to 8 carbon atoms;~~
- ~~– a saturated heterocyclic group chosen from tetrahydrofuryl, tetrahydropyranyl, piperidyl and pyrrolidinyl groups;~~

~~the groups A and B possibly bearing 1 to 3 substituents chosen from a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₆-C₁₄ aryl group, a heteroaryl group chosen from pyridyl, pyrimidyl, pyrrolyl, furyl and thienyl, a (C₆-C₁₄)aryl(C₁-C₆)alkyl group, a (C₆-C₁₄)aryl(C₁-C₆)alkyl(C₆-C₁₄)aryl group, a halogen or a trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, nitro, amino, carboxyl, (C₁-C₆)alkoxycarbonyl, carbamoyl, (C₁-C₆)alkylsulfonyl, sulfoamino,~~

~~(C₁-C₆)alkylsulfonylamine, sulfamoyl or (C₁-C₆)alkylcarbonylamino group;~~

~~or two of the substituents forming a methylenedioxy group,~~

- 2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid,
- 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid,
- 2-cyclohexylmethyl-4-(4-methoxyphenyl)-4-oxobutanoic acid,
- 2-benzyl-4-phenyl-4-oxobutanoic acid,
- 2-(β-naphthylmethyl)-4-phenyl-4-oxobutanoic acid,
- 2-benzyl-4-(β-naphthyl)-4-oxobutanoic acid,
- 2-[(4-chlorophenyl)methyl]-4-(4-methoxyphenyl)-4-oxobutanoic acid,
- 2-benzyl-4-(4-methylphenyl)-4-oxobutanoic acid,
- 4-(4-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-4-oxobutanoic acid,
- 2-benzyl-4-(3,4-methylenedioxyphenyl)-4-oxobutanoic acid,
- 2-benzyl-4-cyclohexyl-4-oxobutanoic acid,
- 4-phenyl-2-[(tetrahydrofuran-2-yl)methyl]-4-oxobutanoic acid,
- (-)-2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid,
- (+)-2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid,
- (-)-2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid,
- (+)-2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid or
a solvate, enantiomer or salt thereof or a salt of this acid,
in combination with one or more pharmaceutically acceptable excipients.

2. **(Currently Amended)** A pharmaceutical composition ~~Composition~~
according to Claim 1 for treating diabetes.

3. **(Currently Amended)** A pharmaceutical composition ~~Composition~~
according to claim 1 for treating non-insulin-dependent diabetes.

4. **(Currently Amended)** A pharmaceutical composition ~~Composition~~
according to Claim 1 for treating at least one of the pathologies associated with insulin resistance

syndrome, ~~more particularly chosen from~~ dyslipidaemia, obesity, arterial hypertension, and microvascular complications, and macrovascular complications, ~~for instance~~ atherosclerosis, retinopathies, nephropathies ~~and~~ or neuropathies.

5. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition according to claim 1, ~~characterised in that~~ wherein the weight ratio of (i) ~~α -glycosidase inhibitor miglitol, voglibose or emiglitate~~ to (ii) the acid compound of the formula (I) ranges from 10^{-3} to 40, ~~preferably from 10^{-3} to 10 and better still from 10^{-3} to 5.~~

6. (Currently amended) ~~Pharmaceutical~~ A pharmaceutical composition according to claim 1, ~~characterised in that~~ wherein the α -glucosidase inhibitor is ~~chosen from acarbose, miglitol, voglibose and emiglitate.~~

7. (Currently Amended) A pharmaceutical composition ~~Composition~~ according to claim 1, characterised in that wherein the (ii) acid compound of the formula (I) is ~~chosen from:~~

- ~~— 2 benzyl 4 (4 methoxyphenyl) 4 oxobutanoic acid~~
- ~~— 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid~~
- ~~— or a salt, solvate or enantiomer thereof~~
- ~~— 2 cyclohexylmethyl 4 (4 methoxyphenyl) 4 oxobutanoic acid~~
- ~~— 2 benzyl 4 phenyl 4 oxobutanoic acid~~
- ~~— 2 (β -naphthylmethyl) 4 phenyl 4 oxobutanoic acid~~
- ~~— 2 benzyl 4 (β -naphthyl) 4 oxobutanoic acid~~
- ~~— 2 [(4-chlorophenyl)methyl] 4 (4 methoxyphenyl) 4 oxobutanoic acid~~
- ~~— 2 benzyl 4 (4-methylphenyl) 4 oxobutanoic acid~~
- ~~— 4 (4-fluorophenyl) 2 [(4-methoxyphenyl)methyl] 4 oxobutanoic acid~~
- ~~— 2 benzyl 4 (3,4-methylenedioxyphenyl) 4 oxobutanoic acid~~
- ~~— 2 benzyl 4 cyclohexyl 4 oxobutanoic acid~~
- ~~— 4 phenyl 2 [(tetrahydrofur 2-yl)methyl] 4 oxobutanoic acid,~~

the solvates, enantiomers and salts of these acids.

8. (Currently amended) A pharmaceutical composition ~~Composition~~ according to claim 1 ~~7~~, characterised in that wherein the compound of the formula (I) ~~(ii) acid~~ is chosen from:

- ~~(-) 2-benzyl 4-(4-methoxyphenyl)-4-oxobutanoic acid~~
- ~~— (+) 2-benzyl 4-(4-methoxyphenyl)-4-oxobutanoic acid~~
- ~~(-) 2-benzyl 4-(4-fluorophenyl)-4-oxobutanoic acid~~
- ~~(+)-2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid.~~

- 9. (Currently Amended) A pharmaceutical composition ~~Composition~~ according to claim 1, which is suitable for oral administration.

10. ~~(Withdrawn-Currently Amended)~~ A method for the preparation of a medicinal combination for treating diabetes comprising combining ~~Use of an~~ (i) an α -glucosidase inhibitor that is miglitol, voglibose or emiglitate in combination with a compound of the formula (I) (ii) an acid as defined in Claim 1 ~~for the preparation of a medicinal combination for treating diabetes.~~

11. ~~(Withdrawn-Currently Amended)~~ ~~Use~~ A method according to Claim 10 for the preparation of a medicinal combination for treating non-insulin-dependent diabetes.

12. ~~(Withdrawn-Currently Amended)~~ ~~Use of an α -glucosidase inhibitor in combination with a compound of the formula (I) as defined in Claim 1 for~~ A method for the preparation of a medicinal combination for treating at least one of the pathologies associated with insulin resistance syndrome, more particularly chosen from dyslipidaemia, obesity, arterial hypertension, and microvascular complications, and macrovascular complications, for instance atherosclerosis, retinopathies, nephropathies and or neuropathies comprising (i) an α -glucosidase inhibitor that is miglitol, voglibose or emiglitate combined with (ii) an acid as defined in Claim 1

13. ~~(Withdrawn-Currently Amended)~~ ~~Use~~ A method according to claim 10,

characterised in that wherein the α -glucosidase inhibitor is chosen from acarbose, miglitol, voglibose and emiglitate.

14.(Withdrawn-Currently Amended) Use A method according to claim 10, characterised in that wherein the acid (ii) is compound of the formula (I) is chosen from:

- ~~— 2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid~~
- 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid
- or a salt, solvate or enantiomer thereof
- ~~— 2-cyclohexylmethyl-4-(4-methoxyphenyl)-4-oxobutanoic acid~~
- ~~— 2-benzyl-4-phenyl-4-oxobutanoic acid~~
- ~~— 2-(β -naphthylmethyl)-4-phenyl-4-oxobutanoic acid~~
- ~~— 2-benzyl-4-(β -naphthyl)-4-oxobutanoic acid~~
- ~~— 2-[(4-chlorophenyl)methyl]-4-(4-methoxyphenyl)-4-oxobutanoic acid~~
- ~~— 2-benzyl-4-(4-methylphenyl)-4-oxobutanoic acid~~
- ~~— 4-(4-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-4-oxobutanoic acid~~
- ~~— 2-benzyl-4-(3,4-methylenedioxyphenyl)-4-oxobutanoic acid~~
- ~~— 2-benzyl-4-cyclohexyl-4-oxobutanoic acid~~
- ~~— 4-phenyl-2-[(tetrahydrofuran-2-yl)methyl]-4-oxobutanoic acid,~~
the solvates, enantiomers and salts of these acids.

15.(Withdrawn-Currently Amended) Use A method according to claim 10, characterised in that wherein the medicinal combination is in the form of a unit dose comprising (i) an α -glucosidase inhibitor that is miglitol, voglibose or emiglitate and (ii) a salt compound of the formula (I).

16.(Withdrawn-Currently Amended) Use A pharmaceutical compound according to claim 1, characterised in that wherein the unit dose comprises from 0.1 mg to 400 mg of (i) an α -glucosidase inhibitor that is miglitol, voglibose or emiglitate and from 12.5 to 400 mg of said (ii) compound of the formula (I).

17. (New) A pharmaceutical composition according to claim 5, wherein the weight ratio of (i) to (ii) is from 10^{-3} to 10.

18. (New) A pharmaceutical composition according to claim 17, wherein the weight ratio of (i) to (ii) is from 10^{-3} to 5.